长武县地处陕西省咸阳市西北部，位于陕甘交界处的渭北黄土高原，素有"秦陇门户"之称，是古丝绸之 路的重要驿站。当前，长武县紧扣高质量项目推进年、营商环境突破年、干部作风能力提升年"三个 年"活动主线，聚力打好"八场硬仗"，全面推进产业升级、项目建设和民生改善，奋力谱写中国式现代 化长武实践新篇章。 产业筑基，培育发展新动能 长武县立足资源禀赋，聚焦高端精细化工、装备制造与苹果全产业链三大方向，推动产业集聚化、智能 化、绿色化发展。 农业方面，长武以苹果产业为重点，持续完善全产业链条。全县苹果种植面积稳定在22.5万亩，年产值 超30亿元，品牌价值突破50亿元。依托3000万元果业发展基金，以长兴苹果全产业链园区为重点，推动 品种选育、仓储物流、精深加工与品牌宣传协同发展。中国银行及苏陕协作资金援建的苹果试验示范站 及苗木繁育基地等项目，为产业提质增效注入了新动力。 杨家坪煤矿、鸦儿沟大桥、丽彩化学原料药等一批标杆项目加快推进。其中，杨家坪煤矿总投资88.9亿 元，预计2029年投产；鸦儿沟大桥建成后将惠及34个村5万群众，助力彭公、相公两镇融入县城"10分钟 经济圈"。 招商引资方面，长武坚持"招大、引强、选优 ...

11月21日，华纳药厂跌6.60%，成交额2.03亿元。两融数据显示，当日华纳药厂获融资买入额3142.85万 元，融资偿还7880.02万元，融资净买入-4737.16万元。截至11月21日，华纳药厂融资融券余额合计3.10 亿元。 融资方面，华纳药厂当日融资买入3142.85万元。当前融资余额3.10亿元，占流通市值的5.19%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，华纳药厂11月21日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，湖南华纳大药厂股份有限公司位于湖南省长沙市岳麓区麓天路28号C6-C7栋，成立日期2001 年4月30日，上市日期2021年7月13日，公司主营业务涉及化学原料药、化学药制剂和中药制剂的研发、 生产与销售。主营业务收入构成为：制剂产品73.19%，原料药及中间体25.22%，技术服务1.52%，植物 提取物及食品0.06%，其他0.01%。 截至9月30日，华纳药厂股东户数6416.00，较上期减少11.83%；人均流通股20467股， ...

11月21日，华纳药厂跌5%，截至发稿，报46.17元/股，成交7085.21万元，换手率1.15%，总市值60.63亿 元。华纳药厂股价已经连续5天下跌，区间累计跌幅7.07%。 资料显示，湖南华纳大药厂股份有限公司位于湖南省长沙市岳麓区麓天路28号C6-C7栋，成立日期2001 年4月30日，上市日期2021年7月13日，公司主营业务涉及化学原料药、化学药制剂和中药制剂的研发、 生产与销售。主营业务收入构成为：制剂产品73.19%，原料药及中间体25.22%，技术服务1.52%，植物 提取物及食品0.06%，其他0.01%。 截至发稿，李恭敏累计任职时间11年83天，现任基金资产总规模1.24亿元，任职期间最佳基金回报 28.83%， 任职期间最差基金回报-30.41%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，招商基金旗下1只基金重仓华纳药厂。招商裕泰混合（016375）三季度持有股数7.79万股， 占基金净值比例为3.6%，位 ...

11月21日，东亚药业跌5.04%，截至发稿，报19.58元/股，成交1490.50万元，换手率0.66%，总市值 22.46亿元。东亚药业股价已经连续3天下跌，区间累计跌幅3.87%。 资料显示，浙江东亚药业股份有限公司位于浙江省台州市临海市台州湾经济技术开发区东海第五大道21 号，成立日期1998年2月6日，上市日期2020年11月25日，公司主营业务涉及化学原料药、医药中间体的 研发、生产和销售。主营业务收入构成为：β-内酰胺类抗菌药44.84%，抗胆碱和合成解痉药23.92%， 喹喏酮类抗菌药12.86%，皮肤用抗真菌药8.87%，其他产品5.05%，其他(补充)4.46%。 诺安多策略混合A（320016）成立日期2011年8月9日，最新规模18.55亿。今年以来收益73.37%，同类 排名205/8136；近一年收益70.11%，同类排名214/8056；成立以来收益234.6%。 诺安多策略混合A（320016）基金经理为孔宪政。 截至发稿，孔宪政累计任职时间4年361天，现任基金资产总规模56.08亿元，任职期间最佳基金回报 95.2%， 任职期间最差基金回报-16.74%。 风险提示：市场有 ...

Core Viewpoint - The stock of Te Yi Pharmaceutical has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 35.94%, indicating volatility in its market performance [1]. Company Performance - As of September 30, 2025, Te Yi Pharmaceutical reported a revenue of 6.92 billion yuan, representing a year-on-year growth of 51.86%, and a net profit attributable to shareholders of 652.17 million yuan, which is a significant increase of 985.18% compared to the previous year [2]. - The company has distributed a total of 1.059 billion yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3]. Stock Market Activity - The stock price of Te Yi Pharmaceutical is currently at 12.10 yuan per share, with a trading volume of 2.60 billion yuan and a turnover rate of 5.62%, leading to a total market capitalization of 6.207 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" 11 times this year, with the most recent appearance on November 17, where it recorded a net buy of -733.44 million yuan [1]. Shareholder Information - As of September 30, 2025, the number of shareholders for Te Yi Pharmaceutical increased to 58,100, a rise of 10.11%, while the average circulating shares per person decreased by 9.09% to 6,481 shares [2]. - Among the top ten circulating shareholders, notable positions include the "Xingquan Zhongzheng 800 Six-Month Holding Index Enhanced A" and "Xingquan Hu-Shen 300 Index Enhanced (LOF) A," which maintained their holdings [3].

截至9月30日，华纳药厂股东户数6416.00，较上期减少11.83%；人均流通股20467股，较上期增加 13.42%。2025年1月-9月，华纳药厂实现营业收入10.86亿元，同比增长1.55%；归母净利润2.07亿元，同 比增长30.75%。 分红方面，华纳药厂A股上市后累计派现2.91亿元。近三年，累计派现2.25亿元。 11月14日，华纳药厂跌0.67%，成交额1.61亿元。两融数据显示，当日华纳药厂获融资买入额2459.82万 元，融资偿还2124.81万元，融资净买入335.01万元。截至11月14日，华纳药厂融资融券余额合计3.53亿 元。 融资方面，华纳药厂当日融资买入2459.82万元。当前融资余额3.53亿元，占流通市值的5.17%，融资余 额超过近一年70%分位水平，处于较高位。 融券方面，华纳药厂11月14日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，湖南华纳大药厂股份有限公司位于湖南省长沙市岳麓区麓天路28号C6-C7栋，成立日期2001 年4月30日，上市日 ...

Core Viewpoint - Baiyunshan Pharmaceutical Group has shown a mixed performance in financing activities and stockholder dynamics, with a slight increase in revenue and net profit year-on-year, indicating stable growth in its core business segments [1][2][3] Financing Activities - On November 11, Baiyunshan's financing buy-in amounted to 21.89 million yuan, while financing repayment reached 35.18 million yuan, resulting in a net financing outflow of 13.30 million yuan [1] - The total financing and securities balance for Baiyunshan as of November 11 is 859 million yuan, with the financing balance accounting for 2.23% of the circulating market value, which is above the 70th percentile of the past year [1] - In terms of securities lending, Baiyunshan repaid 1,000 shares and sold 11,000 shares on November 11, with the selling amount calculated at 301,100 yuan, and the remaining securities lending balance is 8.10 million shares [1] Company Overview - Baiyunshan Pharmaceutical Group, established on September 1, 1997, and listed on February 6, 2001, operates in various sectors including traditional Chinese medicine, chemical raw materials, and health management [2] - The company's revenue composition shows that the major commercial segment contributes 69.32%, followed by health products at 16.79%, and traditional medicine at 12.53% [2] - For the period from January to September 2025, Baiyunshan reported a revenue of 61.61 billion yuan, reflecting a year-on-year growth of 4.31%, and a net profit attributable to shareholders of 3.31 billion yuan, up by 4.78% [2] Dividend Distribution - Since its A-share listing, Baiyunshan has distributed a total of 10.91 billion yuan in dividends, with 4.36 billion yuan distributed over the past three years [3] Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders include China Securities Finance Corporation, holding 47.28 million shares, while Hong Kong Central Clearing Limited reduced its holdings by 20.44 million shares [3] - Other notable shareholders include Huatai-PB CSI 300 ETF and E Fund CSI 300 Medical ETF, both of which have seen a decrease in their holdings compared to the previous period [3]

Core Insights - Warner Pharmaceutical reported a revenue of approximately 1.086 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 1.55% [1] - The net profit attributable to shareholders reached about 207 million yuan, marking a significant year-on-year increase of 30.75% [1] - Basic earnings per share were 1.58 yuan, also reflecting a year-on-year increase of 30.58% [1] Financial Performance - Total assets of Warner Pharmaceutical increased to approximately 2.781 billion yuan, a growth of 13.06% compared to the end of the previous year [1] - Revenue composition for the first three quarters included approximately 805 million yuan from formulation products, 262 million yuan from raw materials and intermediates, and 12 million yuan from technical services [1] Company Overview - Established in 2001, Warner Pharmaceutical specializes in the R&D, production, and sales of chemical raw materials, chemical drugs, and traditional Chinese medicine formulations [1] - The company has developed into a key member of Hunan's biopharmaceutical industry chain, with 71 specialty chemical raw material varieties and 59 registered chemical drug formulation approvals [1] R&D Investment - Warner Pharmaceutical has increased its R&D investment to 106 million yuan in the first three quarters of this year, accounting for 9.75% of its operating revenue [2] - The company was recognized in the TOP 100 of the "2025 China Chemical Drug R&D Strength Ranking" at the 2025 PDI Pharmaceutical R&D Innovation Conference [2]

Core Viewpoint - Xinghuo Technology is a significant player in the domestic food and feed additive sector, with a comprehensive business model covering research, production, and sales of food additives, feed additives, chemical raw materials, and pharmaceutical intermediates [1] Group 1: Business Performance - In Q3 2025, Xinghuo Technology achieved a revenue of 12.077 billion yuan, ranking 4th among 24 companies in the industry [2] - The company's net profit for the same period was 1.014 billion yuan, placing it 3rd in the industry [2] Group 2: Financial Ratios - As of Q3 2025, Xinghuo Technology's debt-to-asset ratio was 50.79%, higher than the previous year's 45.73% and above the industry average of 28.46% [3] - The company's gross profit margin was 18.98%, an increase from 15.72% year-on-year, but still below the industry average of 28.77% [3] Group 3: Management Compensation - The total compensation for General Manager Yan Xiaolin was 9.1744 million yuan in 2024, a significant increase of 8.704 million yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 2.44% to 45,900, with an average holding of 27,400 circulating A-shares, up by 10.50% [5] Group 5: Market Outlook - Huatai Securities noted that despite Q3 performance being below expectations due to amino acid and MSG market conditions, the outlook remains positive due to improving breeding demand and new project increments [6] - The feed additive segment generated 8.2 billion yuan in revenue, supported by improved raw material costs, while the food additive segment faced a decline [6]

Core Viewpoint - Xinhua Pharmaceutical's stock price has shown a slight increase of 2.65% year-to-date, but has experienced a decline over the past 60 days, indicating potential volatility in its market performance [1][2]. Company Overview - Xinhua Pharmaceutical, established on November 20, 1998, and listed on August 6, 1997, is located in Zibo, Shandong Province. The company specializes in the development, manufacturing, and sales of chemical raw materials, pharmaceutical preparations, and other products [1]. - The company's main business revenue composition includes: 44.36% from tablets, injections, and capsules; 32.11% from raw materials for antipyretic and analgesic drugs; and 23.53% from pharmaceutical intermediates and others [1]. Financial Performance - For the period from January to September 2025, Xinhua Pharmaceutical achieved an operating income of 6.763 billion yuan, representing a year-on-year growth of 0.42%. However, the net profit attributable to shareholders decreased by 25.53% to 256 million yuan [2]. - The company has distributed a total of 1.17 billion yuan in dividends since its A-share listing, with 495 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Xinhua Pharmaceutical was 70,700, a decrease of 7.60% from the previous period. The average circulating shares per person remained at 0 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 3.1337 million shares, a decrease of 275,600 shares from the previous period [3].